{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:51:43Z","timestamp":1785531103751,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00488-w","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:22:15Z","timestamp":1743715335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of different intervention thresholds for the treatment of glucocorticoid-induced osteoporosis: a cross-sectional study"],"prefix":"10.1186","volume":"9","author":[{"given":"Kanchalee","family":"Puksun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatlert","family":"Pongchaiyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattapol","family":"Pakchotanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongthorn","family":"Narongroeknawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornsawan","family":"Leosuthamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thunyawarin","family":"Arunthanachaikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-3559","authenticated-orcid":false,"given":"Sumapa","family":"Chaiamnuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"1","key":"488_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7\u201316.","journal-title":"Endocrine"},{"issue":"1","key":"488_CR2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"488_CR3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274\u201382.","journal-title":"J Clin Invest"},{"issue":"1","key":"488_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI108762","volume":"60","author":"RG Klein","year":"1977","unstructured":"Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977;60(1):253\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"488_CR5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02563820","volume":"46","author":"HA Morris","year":"1990","unstructured":"Morris HA, Need AG, O\u2019Loughlin PD, Horowitz M, Bridges A, Nordin BE. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1990;46(5):305\u20138.","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"488_CR6","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1053\/meta.2002.35583","volume":"51","author":"G Hampson","year":"2002","unstructured":"Hampson G, Bhargava N, Cheung J, Vaja S, Seed PT, Fogelman I. Low Circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. Metab Clin Exp. 2002;51(11):1458\u201362.","journal-title":"Metab Clin Exp"},{"key":"488_CR7","doi-asserted-by":"crossref","unstructured":"Cano-Garcia L, Manrique-Arija S, Dominguez-Quesada C, Vacas-Perez JC, Armenteros-Ortiz PJ, Ruiz-Vilchez D et al. Sarcopenia and nutrition in elderly rheumatoid arthritis patients: A Cross-Sectional study to determine prevalence and risk factors. Nutrients. 2023;15(11).","DOI":"10.3390\/nu15112440"},{"key":"488_CR8","doi-asserted-by":"crossref","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M et al. 2022 American college of rheumatology guideline for the prevention and treatment of Glucocorticoid-Induced osteoporosis. Arthritis Rheumatol. 2023;75(12):2088\u2013102.","DOI":"10.1002\/art.42646"},{"issue":"2","key":"488_CR9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, et al. The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Min Metab. 2024;42(2):143\u201354.","journal-title":"J Bone Min Metab"},{"issue":"1","key":"488_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.afos.2017.01.001","volume":"3","author":"SS Yeap","year":"2017","unstructured":"Yeap SS, Hew FL, Damodaran P, Chee W, Lee JK, Goh EML, et al. An update of the Malaysian clinical guidance on the management of glucocorticoid-induced osteoporosis, 2015. Osteoporos Sarcopenia. 2017;3(1):1\u20137.","journal-title":"Osteoporos Sarcopenia"},{"issue":"4","key":"488_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.11005\/jbm.2018.25.4.195","volume":"25","author":"SY Park","year":"2018","unstructured":"Park SY, Gong HS, Kim KM, Kim D, Kim HY, Jeon CH, et al. Korean guideline for the prevention and treatment of Glucocorticoid-induced osteoporosis. J Bone Metabolism. 2018;25(4):195\u2013211.","journal-title":"J Bone Metabolism"},{"key":"488_CR12","doi-asserted-by":"crossref","first-page":"908727","DOI":"10.3389\/fendo.2022.908727","volume":"13","author":"MR Laurent","year":"2022","unstructured":"Laurent MR, Goemaere S, Verroken C, Bergmann P, Body JJ, Bruy\u00e8re O, et al. Prevention and treatment of Glucocorticoid-Induced osteoporosis in adults: consensus recommendations from the Belgian bone club. Front Endocrinol. 2022;13:908727.","journal-title":"Front Endocrinol"},{"issue":"2","key":"488_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.afos.2023.06.001","volume":"9","author":"N Charatcharoenwitthaya","year":"2023","unstructured":"Charatcharoenwitthaya N, Jaisamrarn U, Songpatanasilp T, Kuptniratsaikul V, Unnanuntana A, Sritara C, et al. Summary of the Thai osteoporosis foundation (TOPF) clinical practice guideline on the diagnosis and management of osteoporosis 2021. Osteoporos Sarcopenia. 2023;9(2):45\u201352.","journal-title":"Osteoporos Sarcopenia"},{"key":"488_CR14","doi-asserted-by":"crossref","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis international: A journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008;19(4):385\u2013\u200997.","DOI":"10.1007\/s00198-007-0543-5"},{"key":"488_CR15","doi-asserted-by":"crossref","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis international: A journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22(3):809\u2013\u200916.","DOI":"10.1007\/s00198-010-1524-7"},{"issue":"9","key":"488_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Mineral Research: Official J Am Soc Bone Mineral Res. 1993;8(9):1137\u201348.","journal-title":"J Bone Mineral Research: Official J Am Soc Bone Mineral Res"},{"key":"488_CR17","doi-asserted-by":"crossref","unstructured":"Chen J-F, Yu S-F, Chiu W-C, Ko C-H, Hsu C-Y, Lai H-M et al. Development and comparison of treatment decision tools for Glucocorticoid-Induced osteoporosis. Diagnostics (Basel). 2024;14(4):452.","DOI":"10.3390\/diagnostics14040452"},{"issue":"8","key":"488_CR18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/0961203319855122","volume":"28","author":"EL Lai","year":"2019","unstructured":"Lai EL, Huang WN, Chen HH, Hsu CY, Chen DY, Hsieh TY, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus. 2019;28(8):945\u201353.","journal-title":"Lupus"},{"key":"488_CR19","first-page":"1759720x2210744","volume":"14","author":"CC Mok","year":"2022","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY. Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study. Therapeutic Adv Musculoskelet Disease. 2022;14:1759720x221074451.","journal-title":"Therapeutic Adv Musculoskelet Disease"},{"issue":"1","key":"488_CR20","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-022-20016-x","volume":"12","author":"S Moshayedi","year":"2022","unstructured":"Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12(1):15844.","journal-title":"Sci Rep"},{"issue":"10","key":"488_CR21","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP van Staa","year":"2006","unstructured":"van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104\u201312.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"488_CR22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-017-0335-7","volume":"102","author":"M Guler-Yuksel","year":"2018","unstructured":"Guler-Yuksel M, Hoes JN, Bultink IEM, Lems WF. Glucocorticoids, inflammation and bone. Calcif Tissue Int. 2018;102(5):592\u2013606.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"488_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/rheumatology\/kead676","volume":"64","author":"C Richards","year":"2025","unstructured":"Richards C, Stevens R, Lix LM, McCloskey EV, Johansson H, Harvey NC, et al. Fracture prediction in rheumatoid arthritis: validation of FRAX with bone mineral density for incident major osteoporotic fractures. Rheumatology (Oxford). 2025;64(1):228\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"488_CR24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3899\/jrheum.2022-1293","volume":"50","author":"J Mousa","year":"2023","unstructured":"Mousa J, Peterson MN, Crowson CS, Achenbach SJ, Atkinson EJ, Amin S, et al. Validating the fracture risk assessment tool score in a US Population-Based study of patients with rheumatoid arthritis. J Rheumatol. 2023;50(10):1279\u201386.","journal-title":"J Rheumatol"},{"key":"488_CR25","first-page":"204062232210780","volume":"13","author":"SF Yu","year":"2022","unstructured":"Yu SF, Chen MH, Chen JF, Wang YW, Chen YC, Hsu CY, et al. Establishment of a preliminary FRAX(R)-based intervention threshold for rheumatoid arthritis-associated fragility fracture: a 3-year longitudinal, observational, cohort study. Ther Adv Chronic Dis. 2022;13:20406223221078089.","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"488_CR26","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/annrheumdis-2015-208958","volume":"75","author":"C Klop","year":"2016","unstructured":"Klop C, de Vries F, Bijlsma JW, Leufkens HG, Welsing PM. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis. 2016;75(12):2095\u2013100.","journal-title":"Ann Rheum Dis"},{"key":"488_CR27","doi-asserted-by":"crossref","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257\u201376.","DOI":"10.1007\/s00198-012-1958-1"},{"issue":"9","key":"488_CR28","first-page":"1309","volume":"24","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y. [Glucocorticoid and bone. Updated Japanese guidelines for the management of glucocorticoid-induced osteoporosis]. Clin Calcium. 2014;24(9):1309\u201318.","journal-title":"Clin Calcium"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00488-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:23:20Z","timestamp":1743715400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00488-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00488-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Helsinki Declaration and was approved by the Institutional Board Review of the Royal Thai Army Medical Department under approval number IRBRTA 0571\/2566. The consent to participate was waived since this was a retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}